Corvus Pharmaceuticals, Inc. (CRVS) financial statements (2021 and earlier)

Company profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:447811590135
Cash and cash equivalents16539455
Other undisclosed cash, cash equivalents, and short-term investments28737545130
Prepaid expense000  
Other current assets00011
Other undisclosed current assets01100
Total current assets:457911691136
Noncurrent Assets
Operating lease, right-of-use asset22
Property, plant and equipment11233
Long-term investments and receivables37    
Long-term investments37    
Other noncurrent assets01011
Total noncurrent assets:404344
TOTAL ASSETS:868411895140
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities64353
Accounts payable32232
Accrued liabilities00011
Employee-related liabilities22111
Debt 1   
Deferred rent credit  0
Deferred revenue and credits00
Other undisclosed current liabilities65443
Total current liabilities:1210796
Noncurrent Liabilities
Long-term debt and lease obligation12   
Operating lease, liability12
Liabilities, other than long-term debt  111
Other liabilities  111
Other undisclosed noncurrent liabilities(1)    
Total noncurrent liabilities:12111
Total liabilities:13138107
Stockholders' equity
Stockholders' equity attributable to parent727111085133
Common stock00000
Additional paid in capital295288281208201
Accumulated other comprehensive income (loss)00(0)(0)(0)
Accumulated deficit(223)(217)(170)(124)(68)
Total stockholders' equity:727111085133
TOTAL LIABILITIES AND EQUITY:868411895140

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(44)(49)(49)(57)(37)
Other undisclosed operating income0    
Operating loss:(44)(49)(49)(57)(37)
Nonoperating income
(Investment Income, Nonoperating)
37    
Loss from continuing operations before equity method investments, income taxes:(6)(49)(49)(57)(37)
Other undisclosed income from continuing operations before income taxes02211
Net loss available to common stockholders, diluted:(6)(47)(47)(56)(36)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(6)(47)(47)(56)(36)
Comprehensive loss:(6)(47)(47)(56)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)0
Comprehensive loss, net of tax, attributable to parent:(6)(47)(47)(56)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: